Source-grounded facts extracted from Pasithea Therapeutics Corp.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Kartik Krishnan was appointed as Chief Medical Officer at Pasithea Therapeutics Corp..
“On May 4, 2026, Pasithea Therapeutics Corp. (the “Company”) announced the appointment of Kartik Krishnan, M.D., Ph.D. as Chief Medical Officer of the Company, effective May 1, 2026.”
Pasithea Therapeutics Corp. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).
“February 20, 2026, Pasithea Therapeutics Corp. (the “Company”) received a written notice (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market (“Nasdaq”) indicating that the Company is not in compliance with the $1.00 minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market (the “Bid Price Requirement”). The Notice does not result in the immediate delisting of the Company’s common stock from The Nasdaq Capital Market. The Nasdaq Listing Rules require listed securities to maintain a minimum bid pr”
Pasithea Therapeutics Corp.: Increased authorized shares of Common Stock from 100,000,000 to 500,000,000 (effective 2026-01-28).
“On January 28, 2026, the Company filed a Certificate of Amendment (the “Certificate of Amendment”) to the Company’s Second Amended and Restated Certificate of Incorporation, as amended and/or restated from time to time (the “Certificate”), with the Secretary of State of the State of Delaware to increase the number of the Company’s authorized shares of common stock, par value $0.0001 per share (“Common Stock”), from 100,000,000 shares to 500,000,000 shares.”
Pasithea Therapeutics Corp. issued 4,000,000 shares of Common Stock of warrant to H.C. Wainwright & Co., LLC or its designees.
“the Company issued to Wainwright or its designees, warrants (the “ Placement Agent Warrants ”) to purchase up to an aggregate of 4,000,000 shares of Common Stock (the “ Placement Agent Warrant Shares ”) at an exercise price equal to $0.9375 per share”
Pasithea Therapeutics Corp. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).
“June 23, 2025, Pasithea Therapeutics Corp. (the “Company”) received a written notice (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market (“Nasdaq”) indicating that the Company is not in compliance with the $1.00 minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market (the “Bid Price Requirement”). The Notice does not result in the immediate delisting of the Company’s common stock from The Nasdaq Capital Market. The Nasdaq Listing Rules require listed securities to maintain a minimum bid price”
Pasithea Therapeutics Corp. engaged CBIZ CPAs P.C. as its auditor.
“with the approval of the Audit Committee of the Company's Board of Directors, engaged CBIZ as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025”
Pasithea Therapeutics Corp. dismissed Marcum LLP as its auditor.
“On April 23, 2025, the Company dismissed Marcum as the Company's independent registered accounting firm”
Pasithea Therapeutics Corp.: Amended and restated bylaws to be consistent with charter changes and to add exclusive forum provision and adjust notice periods for stockholder proposals (effective 2023-12-29).
“The Board had previously approved an amendment and restatement of the Bylaws (as so amended and restated, the “Restated Bylaws”), to be effective upon the Effective Time, to be consistent with any changes to the Certificate adopted and approved by the Company’s stockholders at the Reconvened Meeting”
Pasithea Therapeutics Corp.: Amended and restated certificate of incorporation to include changes approved by stockholders, such as classified board, removal of stockholder ability to call special meetings, elimination of stockholder action by written consent, and supermajority vote for bylaw amendments (effective 2023-12-29).
“on December 29, 2023, following the Reconvened Meeting, the Company filed the Restated Certificate with the Secretary of State of the State of Delaware implementing the approved changes and the Restated Certificate was effective immediately upon filing”
Pasithea Therapeutics Corp.: Reverse stock split via Certificate of Amendment to Amended and Restated Certificate of Incorporation (effective 2024-01-02).
“On December 28, 2023, Pasithea Therapeutics Corp. (the “Company”) filed a Certificate of Amendment to the Amended and Restated Certificate of Incorporation of the Company with the Secretary of State of the State of Delaware (the “Certificate of Amendment”), reflecting a one-for-twenty reverse stock split”
Pasithea Therapeutics Corp. shareholders approved Ratification of appointment of Marcum LLP as independent registered public accounting firm for fiscal year ending December 31, 2023 at the 2023-12-19 meeting.
“FOR AGAINST ABSTAIN BROKER NON-VOTES 13,742,119 992,581 36,104 N/A”
Pasithea Therapeutics Corp. shareholders approved Approval of the Pasithea Therapeutics Corp. 2023 Stock Incentive Plan at the 2023-12-19 meeting.
“FOR AGAINST ABSTAIN BROKER NON-VOTES 9,196,502 1,520,422 987,467 3,066,413”
Pasithea Therapeutics Corp. shareholders approved Amendment to Certificate of Incorporation to effect a reverse stock split at a specific ratio ranging from one-for-two to one-for-twenty at the 2023-12-19 meeting.
“FOR AGAINST ABSTAIN BROKER NON-VOTES 13,432,469 1,181,664 156,671 N/A”
Pasithea Therapeutics Corp. shareholders approved Election of each of Dr. Tiago Reis Marques, Prof. Lawrence Steinman, Simon Dumesnil, Dr. Emer Leahy and Alfred Novak at the 2023-12-19 meeting.
“The appointment of each of the foregoing directors was approved by a plurality of the votes cast at the Annual Meeting as follows: FOR WITHHELD BROKER NON-VOTES Dr. Tiago Reis Marques 11,433,844 270,547 3,066,413 Prof. Lawrence Steinman 11,434,292 270,099 3,066,413 Simon Dumesnil 11,409,027 295,364 3,066,413 Dr. Emer Leahy 11,408,775 295,616 3,066,413 Alfred Novak 11,369,003 335,388 3,066,413”
Pasithea Therapeutics Corp. received a nasdaq extension granted notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).
“July 19, 2023, the Company received a letter from Nasdaq advising that the Company had been granted a 180-day extension to January 15, 2024, to regain compliance with the Minimum Bid Price Requirement. The Company will continue to monitor the closing bid price of its Common Stock and may, if appropriate, consider implementing available options, including but not limited to, implementing a reverse stock split of its outstanding securities, to regain compliance with the Minimum Bid Price Requirement. If the Company does not regain compliance within the allotted compliance period, Nasdaq will pro”
Pasithea Therapeutics Corp. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).
“January 19, 2023, Pasithea Therapeutics Corp. (the “Company”) received a written notice (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market (“Nasdaq”) indicating that the Company is not in compliance with the $1.00 minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market (the “Bid Price Requirement”). The Notice does not result in the immediate delisting of the Company’s common stock from The Nasdaq Capital Market. The Nasdaq Listing Rules require listed securities to maintain a minimum bid pri”
Pasithea Therapeutics Corp. shareholders rejected Adjournment of Special Meeting at the 2022-12-09 meeting.
“4. To adjourn the Special Meeting to a later date Votes For Votes Against Abstain 6,415,202 10,754,297 1,996,394 The proposal was denied.”
Pasithea Therapeutics Corp. shareholders rejected Repeal of provisions or amendments of Bylaws adopted without stockholder approval at the 2022-12-09 meeting.
“3. To repeal each provision or amendment of the Company’s Bylaws adopted by the Board without the approval of the Company’s stockholders after April 13, 2021 Votes For Votes Against Abstain 6,415,202 10,755,297 1,995,394 The proposal was denied.”
Pasithea Therapeutics Corp. shareholders rejected Filling of vacancies related to removal of directors at the 2022-12-09 meeting.
“2. The filling of any vacancies related to the removal of the directors of the Company Votes For Votes Against Abstain 6,693,557 10,478,142 1,994,194 The proposal was denied.”
Pasithea Therapeutics Corp. shareholders rejected Removal of Emer Leahy as a director at the 2022-12-09 meeting.
“1E. The removal, without cause, of Emer Leahy as a director of the Company: Votes For Votes Against Abstain 6,420,984 10,750,297 1,994,612 The proposal was denied.”
Pasithea Therapeutics Corp. shareholders rejected Removal of Simon Dumesnil as a director at the 2022-12-09 meeting.
“1D. The removal, without cause, of Simon Dumesnil as a director of the Company: Votes For Votes Against Abstain 6,423,202 10,750,897 1,991,794 The proposal was denied.”
Pasithea Therapeutics Corp. shareholders rejected Removal of Lawrence Steinman as a director at the 2022-12-09 meeting.
“1C. The removal, without cause, of Lawrence Steinman as a director of the Company: Votes For Votes Against Abstain 6,420,984 10,750,297 1,994,612 The proposal was denied.”
Pasithea Therapeutics Corp. shareholders rejected Removal of Alfred Novak as a director at the 2022-12-09 meeting.
“1B. The removal, without cause, of Alfred Novak as a director of the Company: Votes For Votes Against Abstain 6,419,802 10,750,297 1,995,794 The proposal was denied.”
Pasithea Therapeutics Corp. shareholders rejected Removal of Dr. Tiago Reis Marques as a director at the 2022-12-09 meeting.
“1A. The removal, without cause, of Dr. Tiago Reis Marques as a director of the Company: Votes For Votes Against Abstain 6,420,984 10,750,297 1,994,612 The proposal was denied.”
Pasithea Therapeutics Corp. entered into Settlement and Cooperation Agreement with Concord IP2 Ltd., Elderhill Corporation, Leonite Capital LLC, Leonite Fund I, LP, Camac Partners, LLC, Camac Capital, LLC, Camac Fund, LP, David Delaney, Avi Geller, and Eric Shahinian (collectively, the "Camac Group") (effective 2022-12-09).
“On December 9, 2022, Pasithea Therapeutics Corp. (“Pasithea” or “Company”) entered into a Settlement and Cooperation Agreement (“Cooperation Agreement”) with Concord IP2 Ltd., Elderhill Corporation, Leonite Capital LLC, Leonite Fund I, LP, Camac Partners, LLC, Camac Capital, LLC, Camac Fund, LP, David Delaney, Avi Geller, and Eric Shahinian (collectively, the “Camac Group”).”
Daniel Schneiderman was appointed as Chief Financial Officer at Pasithea Therapeutics Corp..
“Effective October 11, 2022, Daniel Schneiderman was appointed to serve as the Chief Financial Officer of the Company.”
Alfred J. Novak was appointed as Director at Pasithea Therapeutics Corp..
“Concurrently, the Board appointed Alfred J. Novak to the Board and to its audit committee.”
Yassine Bendiabdallah resigned as Director at Pasithea Therapeutics Corp..
“On September 14, 2022, Dr. Yassine Bendiabdallah resigned from the board of directors (the “Board”) of Pasithea Therapeutics Corp. (the “Company”).”
Stanley Gloss departed as Chief Financial Officer at Pasithea Therapeutics Corp..
“On June 7, 2022, Stanley Gloss, the Chief Financial Officer of Pasithea Therapeutics Corp. (the “Company”), passed away.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.